Some visit links earn us a commission.
Quick verdict
Medvi is the better pick for most patients on overall scoring. Medvi runs a compounded-semaglutide and tirzepatide model at flat monthly pricing, with no lock-in and rapid intake. Comparable to Henry Meds and Mochi on price; less established clinical depth than Form Health or Knownwell. Best fit for cash-pay patients who want predictable monthly cost with minimal friction.
That said, Found wins on specific dimensions. Found has the broadest medication catalog of any program here, spanning branded GLP-1s, compounded options and Lilly's newly approved oral pill, Foundayo (orforglipron). The 12-month commitment required for the lowest price is the catch.
Side-by-side
| Found | Medvi | |
|---|---|---|
| Starts from | $169/mo (incl. medication) | $299/mo (incl. medication) |
| Monthly cost gap | Found is $10/mo cheaper than Medvi | |
| Lock-in | 12-mo lock-in | Month-to-month |
| Time to prescription | 5 days | 2 days |
| Consultation type | Asynchronous | Asynchronous |
| Affiliate network | Impact | Direct |
Score by dimension
Scores out of 10, equal-weighted across five dimensions. How we score. The winner of each dimension is highlighted.
| Found | Medvi | |
|---|---|---|
| Pricing transparency | 6/10 | 8/10 |
| Cancellation terms | 3/10 | 8/10 |
| Onboarding experience | 8/10 | 7/10 |
| Medication options | 9/10 | 7/10 |
| Member reviews | 7.8/10 | 9/10 |
When to choose Found
Best for complex clinical workups
Patients whose obesity medicine clinician has flagged a non-standard medication path (multiple drug classes, off-label combinations or 503A-compounded options that other programs have exited).
Found wins on onboarding experience, medication options and runs $10/mo cheaper than Medvi at the entry tier ($169 vs $179). Over a year that's $120 you keep. The caveat: Patients new to GLP-1s who want a simple month-to-month commitment. The 12-month plan required for the lowest price is the most punitive structure short of WeightWatchers Clinic. Note also: Subject to ongoing Lilly compounded-tirzepatide enforcement risk
When to choose Medvi
Best for flat compounded with no lock-in
Cash-pay patients who want flat predictable compounded GLP-1 pricing with no lock-in and same-week onboarding. Strong fit if you've taken GLP-1 before and want a simple ongoing prescription channel.
Medvi wins on pricing transparency, cancellation terms, member reviews on the dimensional scoring. The caveat: Insurance-pathway shoppers, patients with multiple comorbidities needing clinical depth or anyone wanting branded Wegovy or Zepbound through standard PA. Note also: Compounded GLP-1 carries 503A regulatory exposure; see compounded callout
If cost is your main filter
Found is the cheaper monthly: $169 all-in vs $179 for Medvi. That's $10 a month or $120a year. The 12-month math matters most if you're planning to maintain on GLP-1 long-term. If you're running a 3-month trial, the $30 delta is small against the cost of stopping early on the wrong dose. Insurance changes the picture: if either program runs prior auth and your plan covers Wegovy or Zepbound, branded with copay can beat both cash-pay totals.
If lock-in is your main filter
Found (12-mo lock-in) and Medvi (month-to-month) sit at different cancellation tiers. If you're first-time on a GLP-1 and unsure how you'll tolerate it, Medvi's easier cancellation is the safer trial.
FAQ
Is Found cheaper than Medvi?
Can I switch from Found to Medvi mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart → · Cost guide · Programs guide
